STOCK TITAN

SOPHiA GENETICS (SOPH) president sells 422 shares to cover RSU taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

SOPHiA GENETICS SA President Ross Muken reported an open-market sale of 422 Ordinary Shares at a weighted average price of $5.3803 per share. According to the disclosure, the shares were sold in the open market solely to satisfy tax withholding obligations tied to the vesting of restricted stock units on June 18, 2026, under a pre-established Rule 10b5-1(c) trading plan and were not discretionary trades. Following this small, tax-related transaction, he directly holds 680,489 Ordinary Shares.

Positive

  • None.

Negative

  • None.
Insider Muken Ross
Role President
Sold 422 shs ($2K)
Type Security Shares Price Value
Sale Ordinary Shares 422 $5.3803 $2K
Holdings After Transaction: Ordinary Shares — 680,489 shares (Direct, null)
Footnotes (1)
  1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on June 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.33 to $5.48, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares sold 422 shares Open-market sale to cover tax withholding
Weighted average sale price $5.3803 per share Ordinary Shares sale on open market
Post-transaction holdings 680,489 shares Ordinary Shares held directly after sale
Price range of sales $5.33–$5.48 per share Multiple transactions underlying weighted average price
RSU vesting date June 18, 2026 Tax obligation arose from RSU vesting
Rule 10b5-1(c) trading plan regulatory
"These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan"
A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.
restricted stock units financial
"tax withholding obligations arising in connection with the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax withholding obligations financial
"sold ... in the open market to satisfy tax withholding obligations arising"
open market financial
"Represents shares sold by the Reporting Person in the open market to satisfy tax"
An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Muken Ross

(Last)(First)(Middle)
C/O SOPHIA GENETICS INC.
401 PARK DRIVE, FLOOR 5

(Street)
BOSTON MASSACHUSETTS 02215

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares06/22/2026S422(1)D$5.3803(2)680,489D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on June 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.33 to $5.48, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) President Ross Muken report?

Ross Muken reported selling 422 Ordinary Shares of SOPHiA GENETICS at a weighted average price of $5.3803. The sale was an open-market transaction disclosed on Form 4 and leaves him holding 680,489 Ordinary Shares directly.

Why did SOPHiA GENETICS President Ross Muken sell 422 shares?

The 422 shares were sold to cover tax withholding obligations from the vesting of restricted stock units on June 18, 2026. The filing states these sales were for tax purposes rather than discretionary portfolio decisions.

Was Ross Muken’s SOPHiA GENETICS share sale under a Rule 10b5-1 plan?

Yes. The filing explains the sales were executed under a pre-established Rule 10b5-1(c) trading plan. Such plans schedule trades in advance, indicating the timing was not based on real-time market or company-specific developments.

How many SOPHiA GENETICS shares does Ross Muken hold after this Form 4 sale?

After selling 422 Ordinary Shares, Ross Muken directly owns 680,489 Ordinary Shares of SOPHiA GENETICS. This context shows the reported sale represents a very small portion of his overall direct holdings in the company.

At what prices were the 422 SOPHiA GENETICS shares sold by Ross Muken?

The reported price is a weighted average of $5.3803 per share. The footnotes state the 422 shares were sold in multiple transactions at prices ranging from $5.33 to $5.48 per share, inclusive, across the executed trades.